SCHEDULE: AWM Investment Co. Discloses 5.8% Stake in Aytu BioPharma

AWM Investment Company, Inc. has reported a 5.8% beneficial ownership stake in Aytu BioPharma, Inc. as of December 31, 2025.

Summary

• AWM Investment Company, Inc. (AWM) is the reporting person for this Schedule 13G filing.
• AWM beneficially owns 619,574 shares of Aytu BioPharma, Inc. Common Stock.
• This ownership represents 5.8% of the total class of securities.
• AWM serves as the investment adviser to Special Situations Private Equity Fund, L.P. (SSPE), holding sole voting and investment power over the reported shares.
• The shares were acquired in the ordinary course of business and not for the purpose of changing or influencing control of Aytu BioPharma, Inc.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, typical for a Schedule 13G, which simply discloses a passive beneficial ownership stake without indicating any significant positive or negative developments for the issuer.

Management Comments

• AWM Investment Company, Inc. certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of or with the effect of changing or influencing the control of Aytu BioPharma, Inc.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are routine disclosures by institutional investors who acquire more than 5% of a company's stock, indicating a passive investment intent. This filing signals AWM Investment Company's continued interest in Aytu BioPharma, Inc. without suggesting an active role in management or strategic direction, which is typical for investment advisers managing funds.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional investor's stake, confirming a passive investment approach.

Key Dates

Keywords

Aytu BioPharma, AYTU, AWM Investment Company, Special Situations Private Equity Fund, Beneficial Ownership, Schedule 13G, Investment Adviser, Common Stock